The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.
Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.
Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.
Latest from The University of Texas MD Anderson Cancer Center
Dr. Cortes on BP-100.01 in Patients With Relapsed/Refractory AML
April 1st 2016Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.
Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer
February 12th 2016Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.
Dr. Gershenson on Evolution of Targeted Therapies for Rare Gynecologic Malignancies
February 11th 2016David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.
Dr. Eng on Emerging Agents for Treatment of Anal Cancer
February 8th 2016Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.
James Allison on Exciting Immunotherapy Advancements in Melanoma
December 14th 2015James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.
Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment
November 6th 2015Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.
Dr. Ferrajoli on Treatment of Elderly Patients With CLL
October 22nd 2015Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.
Dr. Shpall on Therapeutic Agents for the Treatment of CLL
October 20th 2015Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.
Dr. Roth Compares Surgery With SBRT in Lung Cancer
September 18th 2015Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.
Dr. Coleman on Next Steps Following ARIEL2 Trial for Ovarian Cancer
September 11th 2015Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.
Alternative Payment Plan Works Only With Large Patient Cohorts
The experiment with bundled care in oncology is moving forward despite mixed results and lingering concerns about the administrative difficulty of implementation, potential care compromises, and whether innovation can thrive under fixed payments.
How a Rebellious Scientist Helped Launch the Modern Age of Immunotherapy
James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
Hope Rises for Immunotherapy in Breast Cancer
March 25th 2015Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.
James Allison Discusses the Potentiation of Checkpoint Blockage with Oncolytic Viruses
August 5th 2014James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
.jpg?fit=crop&auto=format)
